2. Apoptosis Autophagy PI3K/Akt/mTOR
  3. Apoptosis Autophagy PI3K c-Myc
  4. Momordin Ic

Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity.

For research use only. We do not sell to patients.

Momordin Ic Chemical Structure

Momordin Ic Chemical Structure

CAS No. : 96990-18-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 80 In-stock
Solution
10 mM * 1 mL in DMSO USD 80 In-stock
Solid
5 mg USD 60 In-stock
10 mg USD 85 In-stock
25 mg USD 135 In-stock
50 mg USD 190 In-stock
100 mg USD 266 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Momordin Ic:

Momordin Ic Related Antibodies

Top Publications Citing Use of Products

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity[1][2].
In Vitro

Momordin Ic (0-20 μM, 48 h) relies on cholesterol and ganglioside GM1 to enhance the toxicity of recombinant protein MAP30 in breast cancer cells[2].
Momordin Ic (10 μM, 24 h) induces colon cancer cell cycle arrest and apoptosis by inhibiting the SENP1/c-MYC signaling pathway[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Momordin Ic Related Antibodies

Cell Viability Assay[1][2].

Cell Line: HepG2 cell; MDA-MB-231, MCF-7, HepG2, H460, A549, HeLa cells
Concentration: 0-20 μM
Incubation Time: 4 h; 48 h
Result: Inhibited growth in HepG2 cells; Enhanced the cytotoxicity of MAP30 to breast cancer cells.

Apoptosis Analysis[1].

Cell Line: HepG2 cell
Concentration: 0-15 μM
Incubation Time: 4 h
Result: Reduced the protein levels of caspase-3 and Bcl-2, and increased the protein levels of cytochrome c and Bax in the cytoplasmicsol.

Western Blot Analysis[3].

Cell Line: HCT-8 cell, HCT-116 cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Reduced the level of c-Myc protein.
In Vivo

Momordin Ic (12.5, 25, 50 mg/kg, p.o.) accelerates gastrointestinal transport and inhibits gastric emptying in mice by stimulating the synthesis of serotonin (5-HT)[4].
Momordin Ic (10 mg/kg, p.o.) can inhibit ethanol induced gastric mucosal lesions in rats[5].
Momordin Ic (30 mg/kg, once a day for 14 days, p.o.) can reduce CCl4-induced hepatotoxicity in rats[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ddY mice[4].
Dosage: 12.5, 25, 50 mg/kg
Administration: Oral gavage (p.o.)
Result: Accelerated gastrointestinal transit in fasted mice.
Animal Model: Male Sprague-Dawley rat[5].
Dosage: 10 mg/kg
Administration: Oral gavage (p.o.)
Result: Reduced the length of the lesions.
Animal Model: Male Sprague–Dawley rat[6].
Dosage: 30 mg/kg
Administration: Oral gavage (p.o.), once a day for 14 days
Result: Reduced serum transaminase, lactic dehydrogenase, and γ-glutamyltransferase levels in the CCl4-treated rats.
Molecular Weight

764.94

Formula

C41H64O13
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1(C)CC[C@@](CC[C@]2(C)C3=CC[C@@]4([H])[C@@]2(C)CC[C@]5([H])[C@]4(C)CC[C@H](O[C@]6([H])O[C@H](C(O)=O)[C@@H](O)[C@H](O[C@]7([H])OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)C5(C)C)(C(O)=O)[C@@]3([H])C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (130.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.3073 mL 6.5365 mL 13.0729 mL
5 mM 0.2615 mL 1.3073 mL 2.6146 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 6.25 mg/mL (8.17 mM); Clear solution

    This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.71%

SDS (393 KB)

COA (252 KB) HNMR (327 KB) RP-HPLC (250 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.3073 mL 6.5365 mL 13.0729 mL 32.6823 mL
5 mM 0.2615 mL 1.3073 mL 2.6146 mL 6.5365 mL
10 mM 0.1307 mL 0.6536 mL 1.3073 mL 3.2682 mL
15 mM 0.0872 mL 0.4358 mL 0.8715 mL 2.1788 mL
20 mM 0.0654 mL 0.3268 mL 0.6536 mL 1.6341 mL
25 mM 0.0523 mL 0.2615 mL 0.5229 mL 1.3073 mL
30 mM 0.0436 mL 0.2179 mL 0.4358 mL 1.0894 mL
40 mM 0.0327 mL 0.1634 mL 0.3268 mL 0.8171 mL
50 mM 0.0261 mL 0.1307 mL 0.2615 mL 0.6536 mL
60 mM 0.0218 mL 0.1089 mL 0.2179 mL 0.5447 mL
80 mM 0.0163 mL 0.0817 mL 0.1634 mL 0.4085 mL
100 mM 0.0131 mL 0.0654 mL 0.1307 mL 0.3268 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Momordin Ic Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Momordin Ic96990-18-0ApoptosisAutophagyPI3Kc-MycPhosphoinositide 3-kinaseMyctriterpenoid saponinsgastric emptyinghepatotoxicityHepG2 cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Momordin Ic
Cat. No.:
HY-N0330
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.